RYR3 gene polymorphisms and cardiovascular disease outcomes in the context of antihypertensive treatment

Pharmacogenomics Journal

Volumn 13, Issue 4, 2013, Pages 330-334

  Lynch, A I ^a   Irvin, M R ^a   Boerwinkle, E ^b   Davis, B R ^c   Vaughan, L K ^a   Ford, C E ^c   Aissani, B ^a   Eckfeldt, J H ^d   Arnett, D K ^a   Shrestha, S ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Calcium channel blocker; Coronary heart disease; Genetic interaction; Heart failure; Hypertension; RYR3 gene

Indexed keywords

AMLODIPINE; CHLORTALIDONE; DOXAZOSIN; LISINOPRIL; RYANODINE RECEPTOR 3;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; FEMALE; GENE INTERACTION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RYR3 GENE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84881160817     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2012.22     Document Type: Article

References (20)

1. Keenan NL, Rosendorf KA. Prevalence of hypertension and controlled hypertension-United States, 2005-2008. MMWR Surveill Summ 2010; 60(Suppl): 94-97.
2. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010; 303: 2043-2050.
3. Cartwright EJ, Oceandy D, Austin C, Neyses L. Ca2+ signalling in cardiovascular disease: the role of the plasma membrane calcium pumps. Sci China Life Sci 2011; 54: 691-698.
4. Kohler R, Brakemeier S, Kuhn M, Degenhardt C, Buhr H, Pries A et al. Expression of ryanodine receptor type 3 and TRP channels in endothelial cells: comparison of in situ and cultured human endothelial cells. Cardiovasc Res 2001; 51: 160-168.
5. Shrestha S, Irvin MR, Taylor KD, Wiener HW, Pajewski NM, Haritunians T et al. A genome-wide association study of carotid atherosclerosis in HIV-infected men. AIDS 2010; 24: 583-592.
6. Shibata MC, Leon H, Chatterley T, Dorgan M, Vandermeer B. Do calcium channel blockers increase the diagnosis of heart failure in patients with hypertension? Am J Cardiol 2010; 106: 228-235.
7. Yano M. Ryanodine receptor as a new therapeutic target of heart failure and lethal arrhythmia. Circ J 2008; 72: 509-514.
8. Yano M, Yamamoto T, Ikeda Y, Matsuzaki M. Mechanisms of Disease: ryanodine receptor defects in heart failure and fatal arrhythmia. Nat Clin Pract Cardiovasc Med 2006; 3: 43-52.
9. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright Jr JT, Cushman WC et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996; 9(4 Pt 1): 342-360.
10. Arnett DK, Boerwinkle E, Davis BR, Eckfeldt J, Ford CE, Black H. Pharmacogenetic approaches to hypertension therapy: design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study. Pharmacogenomics J 2002; 2: 309-317.
11. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Jama 2000; 283: 1967-1975.
12. Siragy HM. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
13. Currie S, Elliott EB, Smith GL, Loughrey CM. Two candidates at the heart of dysfunction: The ryanodine receptor and calcium/calmodulin protein kinase II as potential targets for therapeutic intervention-An in vivo perspective. Pharmacol Ther 2011; 131: 204-220.
14. Thai TL, Arendshorst WJ. ADP-ribosyl cyclase and ryanodine receptors mediate endothelin ETA and ETB receptor-induced renal vasoconstriction in vivo. Am J Physiol Renal Physiol 2008; 295: F360-F368.
15. Thai TL, Fellner SK, Arendshorst WJ. ADP-ribosyl cyclase and ryanodine receptor activity contribute to basal renal vasomotor tone and agonist-induced renal vasoconstriction in vivo. Am J Physiol Renal Physiol 2007; 293: F1107-F1114.
16. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, de Bakker PI. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 2008; 24: 2938-2939.
17. Ikram MA, Seshadri S, Bis JC, Fornage M, DeStefano AL, Aulchenko YS et al. Genomewide association studies of stroke. N Engl J Med 2009; 360: 1718-1728.
18. Khoury MJ, Flanders WD. Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: case-control studies with no controls!. Am J Epidemiol 1996; 144: 207-213.
19. Davis BR, Ford CE, Boerwinkle E, Arnett D, Eckfeldt J, Black H. Imputing genetreatment interactions when the genotype distribution is unknown using caseonly and putative placebo analyses-a new method for the Genetics of Hypertension Associated Treatment (GenHAT) study. Stat Med 2004; 23: 2413-2427.
20. Yang Q, Khoury MJ, Flanders WD. Sample size requirements in case-only designs to detect gene-environment interaction. Am J Epidemiol 1997; 146: 713-720.